Drug Trial Radar · NCT04143451
Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients
Last checked: Nov 19, 2026Latest source record: Apr 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,000
Planned (sponsor's estimate)
Start
Oct 23, 2019
Primary completion
Sep 30, 2022
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the safety and clinical efficacy (death, overall hospitalization, hospitalization for influenza or pneumonia) of ID QIV delivered via an intradermal device with imiquimod cream pretreatment with conventional intramuscular (IM) standard dose QIV and IM high-dose TIV
Conditions
- Influenza
Interventions
Vaxigrip tetraBiological
quadrivalent influenza vaccine
Fluzone high-doseBiological
high-dose trivalent influenza vaccine
Aldara 5% Topical CreamDrug
imiquimod cream
Aqueous cream BPDrug
inactive aqueous cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 3 years
- Overall hospitalisationTime frame: 3 years
- Hospitalisation for influenzaTime frame: 3 years
- Hospitalisation for pneumoniaTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.